Late Breaking Abstract - Add-on mepolizumab for chronic rhinosinusitis with nasal polyps: SYNAPSE study
C. Hopkins (London, United Kingdom), C. Bachert (Ghent, Belgium), W. Fokkens (Amsterdam, Netherlands), M. Desrosiers (Montreal, Canada), M. Wagenmann (Düsseldorf, Germany), S. Lee (Pittsburgh, United States of America), A. Sousa (Stockley Park, United Kingdom), S. Smith (NC, United States of America), N. Martin (Brentford, United Kingdom), B. Mayer (Stockley Park, United Kingdom), R. Chan (Stockley Park, United Kingdom), J. Han (Norfolk, United States of America)
Source: Virtual Congress 2020 – ALERT: Asthma in adults and children
Session: ALERT: Asthma in adults and children
Session type: Clinical trials session
Number: 4616
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Hopkins (London, United Kingdom), C. Bachert (Ghent, Belgium), W. Fokkens (Amsterdam, Netherlands), M. Desrosiers (Montreal, Canada), M. Wagenmann (Düsseldorf, Germany), S. Lee (Pittsburgh, United States of America), A. Sousa (Stockley Park, United Kingdom), S. Smith (NC, United States of America), N. Martin (Brentford, United Kingdom), B. Mayer (Stockley Park, United Kingdom), R. Chan (Stockley Park, United Kingdom), J. Han (Norfolk, United States of America). Late Breaking Abstract - Add-on mepolizumab for chronic rhinosinusitis with nasal polyps: SYNAPSE study. 4616
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: